Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 358

1.

Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.

Schallier D, Decoster L, Braeckman J, Fontaine C, Degrève J.

Anticancer Res. 2012 Feb;32(2):633-41.

PMID:
22287756
[PubMed - indexed for MEDLINE]
2.

Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.

Heck MM, Thalgott M, Retz M, Wolf P, Maurer T, Nawroth R, Hatzichristodoulou G, Gschwend JE, Kübler H.

BJU Int. 2012 Dec;110(11 Pt B):E635-40. doi: 10.1111/j.1464-410X.2012.11364.x. Epub 2012 Aug 13.

PMID:
22889368
[PubMed - indexed for MEDLINE]
3.

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.

Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P.

BJU Int. 2010 Oct;106(7):974-8. doi: 10.1111/j.1464-410X.2010.09296.x. Epub 2010 Mar 9.

PMID:
20230389
[PubMed - indexed for MEDLINE]
4.

Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer.

Reuter CW, Morgan MA, Ivanyi P, Fenner M, Ganser A, Grünwald V.

World J Urol. 2010 Jun;28(3):391-8. doi: 10.1007/s00345-010-0527-5. Epub 2010 Mar 14.

PMID:
20229232
[PubMed - indexed for MEDLINE]
5.

Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.

Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group.

Clin Cancer Res. 2011 Sep 1;17(17):5765-73. doi: 10.1158/1078-0432.CCR-11-0859. Epub 2011 Jul 25.

PMID:
21788353
[PubMed - indexed for MEDLINE]
Free Article
6.

Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.

Mardjuadi F, Medioni J, Kerger J, D'Hondt L, Canon JL, Duck L, Musuamba F, Oudard S, Clausse M, Moxhon A, Machiels JP.

Cancer Chemother Pharmacol. 2012 Aug;70(2):293-303. doi: 10.1007/s00280-012-1914-y. Epub 2012 Jul 1.

PMID:
22752248
[PubMed - indexed for MEDLINE]
7.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

PMID:
22369348
[PubMed - indexed for MEDLINE]
8.

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.

Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.

J Clin Oncol. 2005 May 20;23(15):3343-51. Epub 2005 Feb 28.

PMID:
15738542
[PubMed - indexed for MEDLINE]
9.

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).

Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ; Alliance for Clinical Trials in Oncology.

Cancer. 2013 Oct 15;119(20):3636-43. doi: 10.1002/cncr.28285. Epub 2013 Jul 31.

PMID:
23913744
[PubMed - indexed for MEDLINE]
10.

Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.

Boehmer A, Anastasiadis AG, Feyerabend S, Nagele U, Kuczyk M, Schilling D, Corvin S, Merseburger AS, Stenzl A.

Anticancer Res. 2005 Nov-Dec;25(6C):4481-6.

PMID:
16334130
[PubMed - indexed for MEDLINE]
Free Article
11.

No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.

Hervonen P, Tulijoki T, Kellokumpu-Lehtinen P.

Anticancer Res. 2012 Aug;32(8):3305-9.

PMID:
22843906
[PubMed - indexed for MEDLINE]
12.

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.

Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF; TAX 327 Investigators.

Ann Oncol. 2008 Oct;19(10):1749-53. doi: 10.1093/annonc/mdn288. Epub 2008 May 16.

PMID:
18487550
[PubMed - indexed for MEDLINE]
Free Article
13.

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.

Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK.

BJU Int. 2008 Feb;101(3):308-12. doi: 10.1111/j.1464-410X.2007.07331.x.

PMID:
18184327
[PubMed - indexed for MEDLINE]
14.

First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K.

Cancer. 2006 Mar 1;106(5):1041-6.

PMID:
16456811
[PubMed - indexed for MEDLINE]
Free Article
15.

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

Fizazi KS, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW.

J Clin Oncol. 2013 May 10;31(14):1740-7. doi: 10.1200/JCO.2012.46.4149. Epub 2013 Apr 8.

PMID:
23569308
[PubMed - indexed for MEDLINE]
16.

The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.

Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S.

Eur J Cancer. 2010 Feb;46(3):517-25. doi: 10.1016/j.ejca.2009.11.007. Epub 2009 Dec 11.

PMID:
20005697
[PubMed - indexed for MEDLINE]
17.

Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel.

Kawahara T, Miyoshi Y, Sekiguchi Z, Sano F, Hayashi N, Teranishi J, Misaki H, Noguchi K, Kubota Y, Uemura H.

PLoS One. 2012;7(10):e48186. doi: 10.1371/journal.pone.0048186. Epub 2012 Oct 30.

PMID:
23118948
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

Hainsworth JD, Meluch AA, Spigel DR, Yost K, Meng C, Greco FA.

Clin Genitourin Cancer. 2006 Mar;4(4):287-92.

PMID:
16729913
[PubMed - indexed for MEDLINE]
19.

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.

J Clin Oncol. 2010 Apr 20;28(12):2070-6. doi: 10.1200/JCO.2009.25.4524. Epub 2010 Mar 22.

PMID:
20308663
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.

Saad F, Ruether D, Ernst S, North S, Cheng T, Perrotte P, Karakiewicz P, Winquist E; Canadian Uro-Oncology Group.

BJU Int. 2008 Aug 5;102(5):551-5. doi: 10.1111/j.1464-410X.2008.07733.x. Epub 2008 May 28.

PMID:
18510661
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk